Just a moment, the page is loading...
Notice to Investigators involved in Pure Substance Request studies: Due to temporary supply issues, there may be a delay in the processing or shipping of pure substances at this time. We apologize for the inconvenience, and we appreciate your understanding.
♥




Efficacy and Safety of DTG/3TC among Treatment-Naïve Individuals

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of DTG/3TC in the treatment of HIV among treatment-naïve individuals. Research of interest may include real-world effectiveness, barrier to resistance, safety and tolerability, patient and provider experience, and health-related quality of life. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.






ViiV ISR Area Of Interest Overview

Drug/Product Alignment
Dolutegravir
Treatment
Area of Interest/DataGap Description
Efficacy/Effectiveness, Experience and Preference
•   What is the efficacy and safety of DTG/3TC in acute HIV infection?
•   What are the treatment outcomes of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals with rapid ART initiation?
•   What is the efficacy and barrier to resistance of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals at risk of non-adherence?
•   What is the impact of DTG/3TC on overall health and wellbeing for treatment naive individuals, as determined by patient reported outcomes and/or patient experience?
•   What are the drivers for DTG/3TC decision/choice among treatment naïve individuals and physicians?
Desirable Study Parameters
Treatment Naïve
Global

Version 20250909-disp



- Back to Top -
© 2026 ViiV Healthcare
Trademarks are owned by or licensed to the ViiV Healthcare group of companies